Co Artemether

# Co artemether (Artemether/Lumefantrine) ## Overview - **Classification**: Antimalarial, Artemisinin-based Combination Therapy (ACT) - **Mechanism**: Artemether is a rapidly acting artemisinin derivative. Lumefantrine is a longer-acting aryl amino alcohol. Both interfere with parasite detoxification of heme, leading to oxidative stress and parasite death. ## Primary Indications 1. **Treatment of uncomplicated *Plasmodium falciparum* malaria** - For patients infected with *P. falciparum* or mixed infections including *P. falciparum*. 2. **Treatment in areas of drug resistance** - Especially where resistance to other antimalarials (e.g., chloroquine, sulfadoxine-pyrimethamine) is high. ## Adult Dosing ### Standard Dosing **Uncomplicated *Plasmodium falciparum* Malaria** - **Dose**: **80 mg artemether / 480 mg lumefantrine** (typically 4 tablets of 20 mg/120 mg) - **Frequency**: Twice daily for 3 days (total 6 doses) - **Route**: Oral - **Duration**: 3 days - **Special Considerations**: Administer with food or milk for optimal absorption. Repeat dose if vomiting occurs within 1-2 hours. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed. Use with caution in severe impairment due to limited data. - **Hepatic Impairment**: No specific dose adjustment for mild to moderate impairment. Use with caution in severe impairment due to limited data. - **Elderly Patients**: No specific dose adjustment; use standard adult dosing. ## Pediatric Dosing ### Neonates (0-28 days) - **Special Notes**: Not routinely recommended due to limited data and potential for toxicity. Consider alternative treatments or specialist consultation. If used, very careful risk-benefit assessment is required. ### Infants (1-12 months) **Uncomplicated *Plasmodium falciparum* Malaria** - **Dose (5 kg to <15 kg)**: **20 mg artemether / 120 mg lumefantrine** (1 tablet of 20 mg/120 mg) - **Frequency**: Twice daily for 3 days (total 6 doses) - **Maximum**: Not applicable as dosing is weight-banded. - **Special Notes**: Ensure crushing tablets and mixing with water for easier administration if infant cannot swallow whole. Administer with food/milk. ### Children (1-12 years) **Uncomplicated *Plasmodium falciparum* Malaria** - **Dose (15 kg to <25 kg)**: **40 mg artemether / 240 mg lumefantrine** (2 tablets of 20 mg/120 mg) - **Dose (25 kg to <35 kg)**: **60 mg artemether / 360 mg lumefantrine** (3 tablets of 20 mg/120 mg) - **Frequency**: Twice daily for 3 days (total 6 doses) - **Maximum**: Not applicable, based on weight band. - **Special Notes**: Administer with food/milk. Can crush tablets and mix with water. ### Adolescents (13-18 years) **Uncomplicated *Plasmodium falciparum* Malaria** - **Dose (>= 35 kg)**: **80 mg artemether / 480 mg lumefantrine** (4 tablets of 20 mg/120 mg) - **Frequency**: Twice daily for 3 days (total 6 doses) - **Maximum**: Adult dose. - **Special Notes**: Administer with food or milk. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to artemether, lumefantrine, or excipients. - **Absolute**: Family history of sudden death or congenital QT prolongation. - **Absolute**: History of cardiac arrhythmias or clinically relevant bradycardia. - **Absolute**: Concomitant use with drugs known to prolong the QT interval (e.g., specific antiarrhythmics, antipsychotics). - **Absolute**: Severe malaria (parenteral treatment needed initially). ### Common Adverse Effects - **Very Common (>10%)**: Headache, dizziness, nausea, vomiting, abdominal pain, anorexia. - **Common (1-10%)**: Palpitations, cough, insomnia, asthenia, arthralgia, myalgia, pruritus, rash. - **Serious but Rare**: Significant QT prolongation, hypersensitivity reactions, severe hepatotoxicity (very rare). ### Key Drug Interactions - **QT-prolonging drugs**: Increased risk of fatal arrhythmias (e.g., quinidine, amiodarone, cisapride). **Avoid concomitant use.** - **Strong CYP3A4 inhibitors**: May increase lumefantrine levels (e.g., ketoconazole, protease inhibitors). Monitor for increased side effects. - **Strong CYP3A4 inducers**: May decrease lumefantrine levels (e.g., rifampicin, phenytoin, carbamazepine, St. John's wort). May lead to treatment failure. **Avoid concomitant use.** - **Oral Contraceptives**: May reduce efficacy of hormonal contraceptives; advise alternative birth control. ## Monitoring & Follow-up - **Before Treatment**: Evaluate cardiac history, concomitant medications, especially those affecting QT interval. Baseline ECG may be considered in high-risk patients. - **During Treatment**: Monitor for resolution of fever and clinical symptoms. Observe for adverse effects, especially gastrointestinal upset. - **Clinical Signs**: Watch for signs of treatment failure (e.g., persistent fever, worsening symptoms). If vomiting occurs, ensure re-dosing. ## Clinical Pearls - 💡 **Administer with food**: Co-artemether absorption is significantly increased with fatty food or milk. This is crucial for efficacy. - 💡 **Complete the full course**: Emphasize adherence to the 3-day, 6-dose regimen, even if feeling better, to prevent recrudescence and drug resistance. - 💡 **Re-dose for vomiting**: If vomiting occurs within 1-2 hours of a dose, re-administer the full dose. - 💡 **Taste considerations**: Tablets can be crushed and mixed with small amounts of water or milk for children. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.